IRCT20230222057495N18
Recruiting
未知
Bioequivalence study of dapagliflozin 10 mg tablet of Viana Darou Sanat pharmaceutical company compared to dapagliflozin 10 mg sample of AstraZeneca company in Australia on healthy volunteers
Viana Darou Sanat Pharmaceutical company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Viana Darou Sanat Pharmaceutical company
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy volunteer between 18 and 55 years old.
- •Body mass index less than 30 kg per square meter.
- •All candidates must be non\-smokers.
Exclusion Criteria
- •Blood pressure less than 90 on 60 mm Hg or more than 140 on 90 mm Hg.
- •Consumption of any drug, alcohol or tobacco within 2 weeks before receiving the drug.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Bioequivalence study of Dapagliflozin 10 mgIRCT20200623047902N37Actover Co.24
Recruiting
Not Applicable
Bioequivalence study of empagliflozin 10 mg tabletIn the present study, no disease was investigated..IRCT20230222057495N3Yab Daro Company24
Completed
Not Applicable
Bioequivalence Study of Dapagliflozin 10 mg Film-coated TabletsHealthyNCT06127212Dexa Medica Group24
Completed
Phase 1
Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed ConditionsHealthy SubjectsNCT04881006Jiangsu Hansoh Pharmaceutical Co., Ltd.30
Completed
Phase 1
Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting ConditionsHealthy SubjectsNCT04880993Jiangsu Hansoh Pharmaceutical Co., Ltd.30